Trial Outcomes & Findings for Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C (NCT NCT01740089)

NCT ID: NCT01740089

Last Updated: 2015-08-18

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE2/PHASE3

Target enrollment

150 participants

Primary outcome timeframe

12 weeks

Results posted on

2015-08-18

Participant Flow

Participant milestones

Participant milestones
Measure
Algeron 1.5 μg/kg
Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
Algeron 2.0 μg/kg
Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
PegIntron
PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). PegIntron: 1.5 μg/kg/week subcutaneously in combination with ribavirin
First 12 Weeks of Treatment
STARTED
50
50
50
First 12 Weeks of Treatment
COMPLETED
50
48
48
First 12 Weeks of Treatment
NOT COMPLETED
0
2
2
After 12 Weeks
STARTED
50
48
48
After 12 Weeks
COMPLETED
43
45
37
After 12 Weeks
NOT COMPLETED
7
3
11

Reasons for withdrawal

Reasons for withdrawal
Measure
Algeron 1.5 μg/kg
Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
Algeron 2.0 μg/kg
Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
PegIntron
PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). PegIntron: 1.5 μg/kg/week subcutaneously in combination with ribavirin
First 12 Weeks of Treatment
Adverse Event
0
1
2
First 12 Weeks of Treatment
Withdrawal by Subject
0
1
0
After 12 Weeks
Lack of Efficacy
3
1
4
After 12 Weeks
Adverse Event
2
0
5
After 12 Weeks
Protocol Violation
1
1
1
After 12 Weeks
Withdrawal by Subject
1
1
1

Baseline Characteristics

Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Algeron 1.5 μg/kg
n=50 Participants
Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
Algeron 2.0 μg/kg
n=50 Participants
Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
PegIntron
n=50 Participants
PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). PegIntron: 1.5 μg/kg/week subcutaneously in combination with ribavirin
Total
n=150 Participants
Total of all reporting groups
Age, Continuous
35 years
n=5 Participants
34 years
n=7 Participants
36 years
n=5 Participants
35 years
n=4 Participants
Sex: Female, Male
Female
13 Participants
n=5 Participants
16 Participants
n=7 Participants
15 Participants
n=5 Participants
44 Participants
n=4 Participants
Sex: Female, Male
Male
37 Participants
n=5 Participants
34 Participants
n=7 Participants
35 Participants
n=5 Participants
106 Participants
n=4 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
1 Participants
n=7 Participants
0 Participants
n=5 Participants
1 Participants
n=4 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
White
50 Participants
n=5 Participants
49 Participants
n=7 Participants
50 Participants
n=5 Participants
149 Participants
n=4 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
Region of Enrollment
Russian Federation
50 participants
n=5 Participants
50 participants
n=7 Participants
50 participants
n=5 Participants
150 participants
n=4 Participants
HCV genotype
HCV 1b
22 participants
n=5 Participants
26 participants
n=7 Participants
26 participants
n=5 Participants
74 participants
n=4 Participants
HCV genotype
HCV 1a
4 participants
n=5 Participants
1 participants
n=7 Participants
2 participants
n=5 Participants
7 participants
n=4 Participants
HCV genotype
HCV 2
2 participants
n=5 Participants
2 participants
n=7 Participants
1 participants
n=5 Participants
5 participants
n=4 Participants
HCV genotype
HCV 3
22 participants
n=5 Participants
21 participants
n=7 Participants
21 participants
n=5 Participants
64 participants
n=4 Participants
Initial Viral load
High (>8х10^5 IU/ml)
17 participants
n=5 Participants
16 participants
n=7 Participants
14 participants
n=5 Participants
47 participants
n=4 Participants
Initial Viral load
Low (≤8х10^5 IU/ml)
33 participants
n=5 Participants
34 participants
n=7 Participants
36 participants
n=5 Participants
103 participants
n=4 Participants
Interleukin 28B (IL-28B) genotype
C/C
19 participants
n=5 Participants
17 participants
n=7 Participants
13 participants
n=5 Participants
49 participants
n=4 Participants
Interleukin 28B (IL-28B) genotype
C/T
24 participants
n=5 Participants
26 participants
n=7 Participants
26 participants
n=5 Participants
76 participants
n=4 Participants
Interleukin 28B (IL-28B) genotype
T/T
7 participants
n=5 Participants
7 participants
n=7 Participants
11 participants
n=5 Participants
25 participants
n=4 Participants

PRIMARY outcome

Timeframe: 12 weeks

Outcome measures

Outcome measures
Measure
Algeron 1.5 μg/kg
n=50 Participants
Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
Algeron 2.0 μg/kg
n=50 Participants
Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
PegIntron
n=50 Participants
PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). PegIntron: 1.5 μg/kg/week subcutaneously in combination with ribavirin
Number of Randomized Patients Achieving Early Virologic Response (EVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) or ≥ 2log10 Decrease of Viral Load After 12 Weeks of Study Treatment.
47 participants
47 participants
44 participants

SECONDARY outcome

Timeframe: 4 weeks

Outcome measures

Outcome measures
Measure
Algeron 1.5 μg/kg
n=50 Participants
Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
Algeron 2.0 μg/kg
n=50 Participants
Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
PegIntron
n=50 Participants
PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). PegIntron: 1.5 μg/kg/week subcutaneously in combination with ribavirin
Number of Randomized Patients Achieving Rapid Virologic Response (RVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) After 4 Weeks of Treatment.
32 participants
28 participants
33 participants

SECONDARY outcome

Timeframe: 24 weeks after last dose of study treatment

Outcome measures

Outcome measures
Measure
Algeron 1.5 μg/kg
n=100 Participants
Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
Algeron 2.0 μg/kg
n=50 Participants
Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
PegIntron
PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). PegIntron: 1.5 μg/kg/week subcutaneously in combination with ribavirin
Number of Randomized Patients Achieving Sustained Virologic Response (SVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) 24 Weeks After Last Dose of Study Treatment.
75 participants
34 participants

SECONDARY outcome

Timeframe: After 24 weeks of treatment for patients with genotype 2 or 3 and after 48 weeks of treatment for patients with genotype 1 or 4.

Outcome measures

Outcome measures
Measure
Algeron 1.5 μg/kg
n=100 Participants
Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
Algeron 2.0 μg/kg
n=50 Participants
Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
PegIntron
PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). PegIntron: 1.5 μg/kg/week subcutaneously in combination with ribavirin
Number of Patients Who Have Undetectable HCV RNA (< 15 IU/ml) at the End of Treatment.
88 participants
38 participants

OTHER_PRE_SPECIFIED outcome

Timeframe: Weeks 0, 12, 24, 48 (for patients with genotype 1 or 4) and 24 weeks after last dose of study treatment

Number of randomized patients with neutralizing antibodies to IFN alfa on weeks 0, 12, 24, 48 (for patients with genotype 1 or 4) and 24 weeks after last dose of study treatment.

Outcome measures

Outcome measures
Measure
Algeron 1.5 μg/kg
n=100 Participants
Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
Algeron 2.0 μg/kg
n=50 Participants
Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). Algeron: 1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
PegIntron
PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg). PegIntron: 1.5 μg/kg/week subcutaneously in combination with ribavirin
Immunogenicity
0 participants
0 participants

Adverse Events

Algeron (n=101)

Serious events: 2 serious events
Other events: 101 other events
Deaths: 0 deaths

PegIntron (n=50)

Serious events: 2 serious events
Other events: 50 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Algeron (n=101)
n=101 participants at risk
The safety analysis included 101 patients received at least 1 dose of Algeron (taking into account one patient withdrawn at early stages of the study due to a protocol violation \[severe depression by the Beck's scale before the first injection\], who was withdrawn from the mITT-analysis)
PegIntron (n=50)
n=50 participants at risk
Reproductive system and breast disorders
dysfunctional uterine bleeding
0.99%
1/101 • Number of events 1
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
0.00%
0/50
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Blood and lymphatic system disorders
drug-induced pancytopenia
0.00%
0/101
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
2.0%
1/50 • Number of events 1
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Surgical and medical procedures
phlegmonous appendicitis
0.99%
1/101 • Number of events 1
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
2.0%
1/50 • Number of events 1
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.

Other adverse events

Other adverse events
Measure
Algeron (n=101)
n=101 participants at risk
The safety analysis included 101 patients received at least 1 dose of Algeron (taking into account one patient withdrawn at early stages of the study due to a protocol violation \[severe depression by the Beck's scale before the first injection\], who was withdrawn from the mITT-analysis)
PegIntron (n=50)
n=50 participants at risk
General disorders
Flu-like syndrome
85.1%
86/101 • Number of events 86
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
98.0%
49/50 • Number of events 49
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
General disorders
Asthenia (weakness, fatigue)
62.4%
63/101 • Number of events 63
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
44.0%
22/50 • Number of events 22
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
General disorders
Grade I decreased body weight
24.8%
25/101 • Number of events 25
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
24.0%
12/50 • Number of events 12
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
General disorders
Grade II decreased body weight
10.9%
11/101 • Number of events 11
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
16.0%
8/50 • Number of events 8
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Nervous system disorders
Headache
51.5%
52/101 • Number of events 52
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
64.0%
32/50 • Number of events 32
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Nervous system disorders
Dizziness
11.9%
12/101 • Number of events 12
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
10.0%
5/50 • Number of events 5
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Psychiatric disorders
Depression
12.9%
13/101 • Number of events 13
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
6.0%
3/50 • Number of events 3
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Psychiatric disorders
Irritability, emotional lability
14.9%
15/101 • Number of events 15
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
8.0%
4/50 • Number of events 4
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Psychiatric disorders
Sleep disorders
8.9%
9/101 • Number of events 9
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
8.0%
4/50 • Number of events 4
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Gastrointestinal disorders
Nausea
13.9%
14/101 • Number of events 14
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
14.0%
7/50 • Number of events 7
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Gastrointestinal disorders
Vomiting
5.9%
6/101 • Number of events 6
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
6.0%
3/50 • Number of events 3
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Gastrointestinal disorders
Stomach pain
8.9%
9/101 • Number of events 9
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
6.0%
3/50 • Number of events 3
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Gastrointestinal disorders
Decreased appetite
9.9%
10/101 • Number of events 10
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
20.0%
10/50 • Number of events 10
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Gastrointestinal disorders
Dry mouth
7.9%
8/101 • Number of events 8
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
4.0%
2/50 • Number of events 2
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Gastrointestinal disorders
Diarrhea
16.8%
17/101 • Number of events 17
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
8.0%
4/50 • Number of events 4
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Respiratory, thoracic and mediastinal disorders
Dry cough
15.8%
16/101 • Number of events 16
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
10.0%
5/50 • Number of events 5
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Respiratory, thoracic and mediastinal disorders
Dyspnoe (including dyspnoe after exercises)
6.9%
7/101 • Number of events 7
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
0.00%
0/50
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Musculoskeletal and connective tissue disorders
Myalgia
29.7%
30/101 • Number of events 30
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
48.0%
24/50 • Number of events 24
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Musculoskeletal and connective tissue disorders
Arthralgia
32.7%
33/101 • Number of events 33
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
32.0%
16/50 • Number of events 16
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Skin and subcutaneous tissue disorders
Alopecia
26.7%
27/101 • Number of events 27
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
24.0%
12/50 • Number of events 12
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Skin and subcutaneous tissue disorders
Skin itch
20.8%
21/101 • Number of events 21
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
14.0%
7/50 • Number of events 7
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Skin and subcutaneous tissue disorders
Rash
13.9%
14/101 • Number of events 14
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
12.0%
6/50 • Number of events 6
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Skin and subcutaneous tissue disorders
Skin dryness and exfoliation
22.8%
23/101 • Number of events 23
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
14.0%
7/50 • Number of events 7
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Skin and subcutaneous tissue disorders
Stomatitis and gingivitis
7.9%
8/101 • Number of events 8
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
6.0%
3/50 • Number of events 3
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Skin and subcutaneous tissue disorders
Blepharitis and conjunctivitis
9.9%
10/101 • Number of events 10
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
6.0%
3/50 • Number of events 3
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Respiratory, thoracic and mediastinal disorders
Rhinitis, nasal congestion
8.9%
9/101 • Number of events 9
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
0.00%
0/50
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Respiratory, thoracic and mediastinal disorders
Hoarseness, throat irritation, sore throat
6.9%
7/101 • Number of events 7
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
8.0%
4/50 • Number of events 4
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Blood and lymphatic system disorders
Grade 1 leucopenia
28.7%
29/101 • Number of events 29
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
26.0%
13/50 • Number of events 13
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Blood and lymphatic system disorders
Grade 2 leucopenia
44.6%
45/101 • Number of events 45
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
46.0%
23/50 • Number of events 23
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Blood and lymphatic system disorders
Grade 3 leucopenia
19.8%
20/101 • Number of events 20
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
22.0%
11/50 • Number of events 11
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Blood and lymphatic system disorders
Grade 1 neutropenia
10.9%
11/101 • Number of events 11
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
20.0%
10/50 • Number of events 10
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Blood and lymphatic system disorders
Grade 2 neutropenia
35.6%
36/101 • Number of events 36
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
28.0%
14/50 • Number of events 14
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Blood and lymphatic system disorders
Grade 3 neutropenia
28.7%
29/101 • Number of events 29
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
26.0%
13/50 • Number of events 13
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Blood and lymphatic system disorders
Grade 4 neutropenia
2.0%
2/101 • Number of events 2
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
2.0%
1/50 • Number of events 1
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Blood and lymphatic system disorders
Grade 1 lymphopenia
7.9%
8/101 • Number of events 8
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
18.0%
9/50 • Number of events 9
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Blood and lymphatic system disorders
Grade 1 thrombocytopenia
46.5%
47/101 • Number of events 47
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
46.0%
23/50 • Number of events 23
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Blood and lymphatic system disorders
Grade 2 thrombocytopenia
5.9%
6/101 • Number of events 6
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
4.0%
2/50 • Number of events 2
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Blood and lymphatic system disorders
Grade 1 anemia
72.3%
73/101 • Number of events 73
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
66.0%
33/50 • Number of events 33
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Blood and lymphatic system disorders
Grade 2 anemia
11.9%
12/101 • Number of events 12
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
16.0%
8/50 • Number of events 8
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
Endocrine disorders
Increased TTH level
11.9%
12/101 • Number of events 12
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.
6.0%
3/50 • Number of events 3
The number of patients for the efficacy analysis was 150. 151 patients were included in the safety analysis, including 1 patient in Algeron group withdrawn at early stages due to a violation of inclusion/non-inclusion criteria \[severe depression at Visit 1\], who was not considered to be enrolled in the study due to serious protocol violation.

Additional Information

Yulia Linkova Medical Director

Biocad

Phone: +7 (495) 992 66 28

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place